# Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/vandetanib-zd6474-an-orally-available-receptor-tyrosine-kinase-inhibitor-that/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Roy S. Herbst,John V. Heymach,Michael S. O’Reilly,Amir Onn,Anderson J. Ryan |
| Citations | 144 |
| DOI | 10.1517/13543784.16.2.239 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2147289344 |
| PMID | 17243944 |
| Type | article |
| Year | 2007 |

## Paper authors

- [John V. Heymach](https://scholariq.org/researchers/john-v-heymach/)
- [Amir Onn](https://scholariq.org/researchers/amir-onn/)

## Paper journal

- [Expert Opinion on Investigational Drugs](https://scholariq.org/journals/expert-opinion-on-investigational-drugs/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.